Cardiovascular safety of NSAIDs: case–control analysis
This article has no abstract so we have provided the first paragraph of the full text.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the relief of joint pain caused by arthritis. Within this class of drugs, cyclo-oxygenase 2 inhibitors have been developed to avoid the problem of gastrointestinal side effects. Recently, however, cyclo-oxygenase 2 inhibitors have been linked to an increased risk of cardiovascular complications—one such drug, rofecoxib, has been withdrawn from the market as a consequence. Two researchers from Nottingham University in the UK have now carried out a case–control study to examine the cardiovascular safety of rofecoxib and other NSAIDs.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
